Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment
NCT05981118Phase 3Enrolling by invitation
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tapinarof in psoriasis (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Post-inflammatory pigment alteration at 12 weeks. Started Jul 2024; status: enrolling by invitation.
02
Drugs
tapinarof
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05981118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981118.